TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

RIVOPHARM

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

RIVOPHARM

ST13

US500000079026596

Classe

5

Pedido

79026596

Registro

3340188

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

34

Atualização mais recente

18/11/2018

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5

Data de depósito

25/07/2006

Data de registro

20/11/2007

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

27/06/2014

Última transação

18/11/2018

Escritório responsável

United States Patent and Trademark Office

Código da situação

709

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

CH-6928 Manno, CH

Examinador

BELZER, LYDIA M

Unidade examinadora

L80

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

RIVOPHARM S.A.

Representantes

RIVOPHARM SA

Classificação técnica

Classes Nice

Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical preparations, both prescription and over-the-counter, namely pharmaceutical preparations for peptic ulcer and gastroesophageal reflux disease (GORD), propulsives, intestinal anti-infectives, intestinal anti-inflammatory agents, oral pharmaceutical preparations for lowering blood glucose, Vitamin A and D, mixed vitamin preparations consisting of vitamins A and D, vitamin and mineral preparations for medical use, vitamin C in the nature of ascorbic acid, mixed vitamin preparations consisting partially of Vitamin C, calcium supplements, mineral supplements, anti-thrombotic agents, intravenous solutions, cardiac glycosides, class I and class III anti-arrhythmics, pharmaceutical preparations for cardiac stimulation excluding cardiac glycosides, Vasodilators used in the treatment of cardiac diseases, anti-adrenergic agents, pharmaceutical preparations for acting on arteriolar smooth muscle, Beta blocking agents, Selective calcium channel blockers, pharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitors, pharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitors combined with other pharmaceutical preparations, anti-fungals for systemic use, anti-infectives and antiseptics, excluding those combined with corticosteroids, oxytocics, plain corticosteroids for systemic use, thyroid preparations, anti-thyroid preparations, tetracyclines preparations, macrolides, lincosamides and streptogramins, aminoglycoside antibacterials, quinolone antibacterials, antimycotics for systemic use, direct acting antivirals, immune sera, bacterial vaccines, alkylating agents, anti-metabolites, plant alkaloids, cytotoxic antibiotics, hormone antagonists and related agents, namely anti-estrogens, anti-androgens and enzyme inhibitors, immunosuppressive agents, anti-inflammatory and anti-rheumatic preparations, non-steroids in the nature of butylpyrazolidines, acetic acid derivatives, oxicams, propionic acid derivatives, fenamates, Coxibs, muscle relaxants, peripherally acting agents in the nature of curare alkaloids and choline derivatives, antigout preparations, analgesics and antipyretics preparations, anti-migraine preparations, anti-epileptic preparations, anti-cholinergic agents, dopaminergic agents, anti-psychotics, anxiolytics, hypnotics and sedatives, antidepressants, parasympathomimetics, agents for use against amoebiasis and other protozoal diseases, anti-malarial preparation, adrenergics, inhalant anesthetics, adrenergics for systemic use, antihistamines for systemic use, diuretic agents

Publicações

Histórico de despachos e eventos da marca no USPTO.

34 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

03/11/2017

GPNX

NOTIFICATION PROCESSED BY IB

13/10/2017

RFNT

REFUSAL PROCESSED BY IB

09/12/2016

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

24/07/2015

INTS

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

06/07/2015

INPC

INVALIDATION PROCESSED

06/07/2015

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

27/02/2015

C71T

CANCELLED SECTION 71

27/06/2014

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

05/06/2009

FICS

FINAL DISPOSITION NOTICE SENT TO IB

27/02/2008

FIMP

FINAL DISPOSITION PROCESSED

27/02/2008

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

20/02/2008

R.PR

REGISTERED-PRINCIPAL REGISTER

20/11/2007

PUBO

PUBLISHED FOR OPPOSITION

04/09/2007

NPUB

NOTICE OF PUBLICATION

15/08/2007

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

29/05/2007

ALIE

ASSIGNED TO LIE

29/05/2007

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

10/05/2007

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

18/04/2007

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

18/04/2007

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

18/04/2007

CNRT

NON-FINAL ACTION MAILED

06/02/2007

CNRT

NON-FINAL ACTION WRITTEN

05/02/2007

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

15/01/2007

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

15/01/2007

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

15/01/2007

RFNT

REFUSAL PROCESSED BY IB

05/01/2007

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

18/12/2006

RFRR

REFUSAL PROCESSED BY MPU

18/12/2006

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

14/12/2006

CNRT

NON-FINAL ACTION WRITTEN

13/12/2006

DOCK

ASSIGNED TO EXAMINER

06/12/2006

NWAP

NEW APPLICATION ENTERED

08/09/2006

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

07/09/2006

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace RIVOPHARM ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.